Login / Signup

Early cirrhosis and a preserved bone marrow niche favour regenerative response to growth factors in decompensated cirrhosis.

Lovkesh AnandChhagan BihariChandan K KedarisettySheetalnath B RoogeDhananjay KumarSmriti ShubhamGuresh KumarAmrish SahneyManoj Kumar SharmaRakhi MaiwallAnupam KumarShiv Kumar Sarin
Published in: Liver international : official journal of the International Association for the Study of the Liver (2018)
Early DC (MELD < 16) patients with mild-moderate ascites and those with a healthy cellular baseline BM respond better to growth factor therapy. Addition of EPO to G-CSF provides better regenerative response than G-CSF monotherapy.
Keyphrases
  • growth factor
  • mesenchymal stem cells
  • stem cells
  • bone marrow
  • cell therapy
  • heart failure
  • tissue engineering
  • dendritic cells
  • high intensity
  • clinical trial
  • cell free
  • immune response
  • study protocol
  • replacement therapy